In 2017, the total prevalent population of Schizophrenia in the 7MM was 5,616,463. Among 7MM, the EU5 countries occupied 22.47% of the patient pool in 2017.
The market size of Schizophrenia in 7MM was USD 6,066.97 million in 2017.
The key companies in the Schizophrenia market include Rovi Pharmaceuticals Laboratories, Minerva Neurosciences, Sunovion/PsychoGenics, Acadia Pharmaceuticals, Forum Pharmaceuticals, BioXcel Therapeutics, Avineuro Pharmaceuticals, Alkermes, Avanir Pharmaceuticals/Otsuka Pharmaceutical/Concert Pharmaceuticals, H. Lundbeck A/S, GW Research, Boehringer Ingelheim, Karuna Pharmaceuticals, Takeda, SyneuRx International, Biogen, Cerevel Therapeutics/Pfizer, Concert Pharmaceuticals, Newron Pharmaceuticals, Corcept Therapeutics, Merck, and Celon Pharma.
For more details, visit: https://www.delveinsight.com/report-store/schizophrenia-market